A detailed history of Aurora Investment Counsel transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Aurora Investment Counsel holds 32,350 shares of HALO stock, worth $1.52 Million. This represents 1.07% of its overall portfolio holdings.

Number of Shares
32,350
Previous 45,103 28.28%
Holding current value
$1.52 Million
Previous $2.36 Million 21.64%
% of portfolio
1.07%
Previous 1.47%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$51.3 - $64.42 $654,228 - $821,548
-12,753 Reduced 28.28%
32,350 $1.85 Million
Q2 2024

Aug 22, 2024

BUY
$37.81 - $52.4 $5,822 - $8,069
154 Added 0.34%
45,103 $2.36 Million
Q1 2024

Jun 04, 2024

BUY
$33.68 - $41.95 $262,468 - $326,916
7,793 Added 20.97%
44,949 $1.83 Million
Q4 2023

Feb 20, 2024

BUY
$33.32 - $42.1 $63,141 - $79,779
1,895 Added 5.37%
37,156 $1.37 Million
Q3 2023

Nov 22, 2023

BUY
$36.46 - $44.03 $1.29 Million - $1.55 Million
35,261 New
35,261 $1.35 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.54B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Aurora Investment Counsel Portfolio

Follow Aurora Investment Counsel and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aurora Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Aurora Investment Counsel with notifications on news.